IMAP advised Prodiagnostics on sale to Indutrade. IMAP is pleased to announce that Indutrade has signed an agreement to acquire all shares in the Swedish medical technology company Prodiagnostics Scandinavia.
Headquartered in Vellinge, outside Malmö, Prodiagnostics is a leading Swedish supplier of drug tests and offers a wide range of rapid tests and laboratory analysis. The company was founded in 2012 by Susanne Nidemar and provides market leading tests in the Swedish market in terms of sensitivity and tracking time.
Prodiagnostics has two business areas: Professional use and workplace testing. Customer groups in professional use include healthcare providers, municipalities and private healthcare actors, as well as law enforcement and customs. Its workplace testing customers are are private companies using tests on their employees.
Indutrade is an international technology and industrial group consisting of over 200 companies in around 30 countries, mainly in Europe. Its turnover in 2021 amounted to $2.2 billion and its shares are listed on Nasdaq Stockholm. The acquisition of Prodiagnostics strengthens the company’s cluster of medical technology companies.
The IMAP Sweden team, led by Jörgen Larsson, Tim Persson and Per Demuth, advised Indutrade on the sale, running a structured and efficient process with great interest from many players. Susanne Nidemar, CEO and previous owner of Prodiagnostics will remain CEO of the company after the change of ownership, confident that Indutrade will be able to provide the resources, skills and knowledge needed to take the company to the next level.
Commenting on IMAP’s involvement, Nidemar said: “IMAP really made me feel secure throughout this, at times, time-consuming process. They have guided me through all the steps in a very professional way and with 100% commitment.”
Do you have any questions?Contact Us